JP2019522037A5 - - Google Patents

Download PDF

Info

Publication number
JP2019522037A5
JP2019522037A5 JP2019504916A JP2019504916A JP2019522037A5 JP 2019522037 A5 JP2019522037 A5 JP 2019522037A5 JP 2019504916 A JP2019504916 A JP 2019504916A JP 2019504916 A JP2019504916 A JP 2019504916A JP 2019522037 A5 JP2019522037 A5 JP 2019522037A5
Authority
JP
Japan
Prior art keywords
hours
hour
vivo
cell
adjusted according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019504916A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019522037A (ja
JP6885629B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/043979 external-priority patent/WO2018022771A1/en
Publication of JP2019522037A publication Critical patent/JP2019522037A/ja
Publication of JP2019522037A5 publication Critical patent/JP2019522037A5/ja
Priority to JP2021078313A priority Critical patent/JP7208659B2/ja
Application granted granted Critical
Publication of JP6885629B2 publication Critical patent/JP6885629B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019504916A 2016-07-29 2017-07-26 インドリノン化合物の使用 Active JP6885629B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021078313A JP7208659B2 (ja) 2016-07-29 2021-05-06 インドリノン化合物の使用

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US201662368707P 2016-07-29 2016-07-29
US62/368,707 2016-07-29
US201662417572P 2016-11-04 2016-11-04
US62/417,572 2016-11-04
US201662422504P 2016-11-15 2016-11-15
US62/422,504 2016-11-15
US201662426107P 2016-11-23 2016-11-23
US62/426,107 2016-11-23
US201762503238P 2017-05-08 2017-05-08
US62/503,238 2017-05-08
US201762534067P 2017-07-18 2017-07-18
US62/534,067 2017-07-18
PCT/US2017/043979 WO2018022771A1 (en) 2016-07-29 2017-07-26 Uses of indolinone compounds

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2020204766A Division JP7182304B2 (ja) 2016-07-29 2020-12-10 インドリノン化合物の使用
JP2021078313A Division JP7208659B2 (ja) 2016-07-29 2021-05-06 インドリノン化合物の使用

Publications (3)

Publication Number Publication Date
JP2019522037A JP2019522037A (ja) 2019-08-08
JP2019522037A5 true JP2019522037A5 (OSRAM) 2019-10-17
JP6885629B2 JP6885629B2 (ja) 2021-06-16

Family

ID=61011754

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019504916A Active JP6885629B2 (ja) 2016-07-29 2017-07-26 インドリノン化合物の使用
JP2020204766A Active JP7182304B2 (ja) 2016-07-29 2020-12-10 インドリノン化合物の使用
JP2021078313A Active JP7208659B2 (ja) 2016-07-29 2021-05-06 インドリノン化合物の使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020204766A Active JP7182304B2 (ja) 2016-07-29 2020-12-10 インドリノン化合物の使用
JP2021078313A Active JP7208659B2 (ja) 2016-07-29 2021-05-06 インドリノン化合物の使用

Country Status (11)

Country Link
US (4) US10159660B2 (OSRAM)
EP (1) EP3490553B1 (OSRAM)
JP (3) JP6885629B2 (OSRAM)
KR (2) KR102282794B1 (OSRAM)
CN (2) CN114569606B (OSRAM)
CA (1) CA3029851A1 (OSRAM)
MX (1) MX395539B (OSRAM)
PH (1) PH12019500070A1 (OSRAM)
SG (1) SG11201811661TA (OSRAM)
TW (2) TWI780061B (OSRAM)
WO (1) WO2018022771A1 (OSRAM)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9604927B2 (en) * 2014-10-09 2017-03-28 Oncternal Therapeutics, Inc. Indolinone compounds and uses thereof
KR102375929B1 (ko) 2016-03-31 2022-03-16 온크터널 테라퓨틱스, 인코포레이티드. 인돌린 유사체 및 이의 용도
CN114569606B (zh) * 2016-07-29 2024-04-19 英克特诺治疗公司 吲哚啉酮化合物的用途
CN110818611B (zh) * 2018-08-13 2023-01-24 中国科学院上海药物研究所 一类吲哚酮类化合物、其制备方法、药物组合物和用途
US20200171001A1 (en) * 2018-11-30 2020-06-04 Aptose Biosciences Inc. Combination therapy with 2,3-dihydro-isoindole-1-one compounds and methods for treating patients with various mutations
US20240299558A1 (en) * 2021-06-18 2024-09-12 University Of Maryland, Baltimore Proteolysis targeting chimeras and polypharmacological agents targeting bcl-2, and methods of use thereof
MX2024000795A (es) * 2021-07-16 2024-03-25 Celator Pharmaceuticals Inc Metodos para preparar formulaciones liposomales.
WO2025235561A1 (en) * 2024-05-08 2025-11-13 Enspire Group LLC Venetoclax oral drugs and uses thereof

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1288436C (en) 1983-07-22 1991-09-03 David Paul Hesson Phenylquinolinecarboxylic acids and derivatives as antitumor agents
EP1135123B1 (en) 1998-12-04 2004-12-29 Neurosearch A/S Use of isatin derivatives as ion channel activating agents
UA75054C2 (uk) 1999-10-13 2006-03-15 Бьорінгер Інгельхайм Фарма Гмбх & Ко. Кг Заміщені в положенні 6 індолінони, їх одержання та їх застосування як лікарського засобу
AU2001241798A1 (en) 2000-02-28 2001-09-12 Sugen, Inc. 3-(pyrolyllactone)-2-indolinone compounds as kinase inhibitors
CN1155572C (zh) 2001-01-19 2004-06-30 中国人民解放军军事医学科学院毒物药物研究所 吲哚类衍生物及其抗肿瘤用途
US20030157486A1 (en) 2001-06-21 2003-08-21 Graff Jonathan M. Methods to identify signal sequences
AU2005323437B2 (en) 2004-04-30 2011-10-06 Alnylam Pharmaceuticals, Inc. Oligonucleotides comprising a C5-modified pyrimidine
AR056317A1 (es) 2005-04-20 2007-10-03 Xenon Pharmaceuticals Inc Compuestos de oxindol y composicion farmaceutica
US20090217390A1 (en) 2005-04-29 2009-08-27 Fernando Lecanda Cordero Non-human animal sarcoma model
WO2008046083A2 (en) 2006-10-12 2008-04-17 Xenon Pharmaceuticals Inc. Use of oxindole compounds as therapeutic agents
US8232310B2 (en) 2006-12-29 2012-07-31 Georgetown University Targeting of EWS-FLI1 as anti-tumor therapy
EP2687206B1 (en) 2006-12-29 2017-12-13 Georgetown University Targeting of EWS-FLI1 as anti-tumor therapy
WO2008130669A1 (en) 2007-04-20 2008-10-30 The Research Foundation Of State University Of New York Benzimidazoles and pharmaceutical compositions thereof
US8377992B2 (en) 2007-10-22 2013-02-19 The Wistar Institute TRBD-binding effectors and methods for using the same to modulate telomerase activity
EP3401684B1 (en) 2008-10-10 2022-03-16 Dana Farber Cancer Institute, Inc. Chemical modulators of pro-apoptotic bax and bcl-2 polypeptides
JP5675629B2 (ja) 2008-10-21 2015-02-25 オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． ペプチドエポキシケトンを用いた併用療法
WO2010083505A1 (en) 2009-01-19 2010-07-22 The Trustees Of The University Of Pennsylvania Method of treating cancer using a survivin inhibitor
AR078161A1 (es) * 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
WO2012078519A2 (en) 2010-12-06 2012-06-14 Numerate, Inc. 3-acylidene-2-oxoindole derivatives for inhibition of transglutaminase 2
CN102516152B (zh) 2011-12-12 2014-12-10 华东师范大学 一种α-二氟羰基取代的手性叔醇类化合物及其合成方法和应用
US20130259927A1 (en) 2012-04-02 2013-10-03 Gradalis, Inc. Ewing's Sarcoma Bifunctional shRNA Design
EP2836481B1 (en) 2012-04-12 2018-12-26 Georgetown University Compounds and compositions for treating ewings sarcoma family of tumors
MX2015000804A (es) 2012-07-20 2016-03-11 Star Biotechnology Llc Composiciones y metodos para tratar el sarcoma de ewing y otros trastornos relacionados con ews-fli1.
WO2014160183A1 (en) 2013-03-13 2014-10-02 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Methods for modulating chemotherapeutic cytotoxicity
BR112015025711A8 (pt) * 2013-04-08 2019-12-17 Janssen Pharmaceutica Nv uso de ibrutinibe e coposição farmacêutica compreendendo ibrutinibe e um agente anticâncer
HK1217484A1 (zh) * 2013-04-26 2017-01-13 百济神州有限公司 取代的5-(3，5-二甲基异恶唑-4-基)二氢吲哚-2-酮类衍生物
KR101500363B1 (ko) * 2013-07-01 2015-03-16 현대자동차 주식회사 하이브리드 자동차의 동력전달장치
KR20160037201A (ko) * 2013-08-06 2016-04-05 온코에틱스 게엠베하 Bet-브로모도메인 억제제를 사용한 미만성 거대 b-세포 림프종 (dlbcl)의 치료 방법
CN103435606A (zh) 2013-08-22 2013-12-11 中国药科大学 CDK2与GSK3β双重抑制剂及用途
US9511050B2 (en) 2013-10-24 2016-12-06 Georgetown University Methods and compositions for treating cancer
TWI660739B (zh) * 2013-10-25 2019-06-01 製藥公司 使用布魯頓氏酪胺酸激酶抑制劑之治療及免疫療法
WO2015078929A1 (en) * 2013-11-27 2015-06-04 Oncoethix Sa Method of treating leukemia using pharmaceutical formulation containing thienotriazolodiazepine compounds
RU2646758C2 (ru) * 2013-12-05 2018-03-07 Ф. Хоффманн-Ля Рош Аг Гетероарил пиридоны и азапиридоны с электрофильной функциональностью
WO2015160868A1 (en) 2014-04-16 2015-10-22 Signal Pharmaceuticals, Llc Methods for treating cancer using tor kinase inhibitor combination therapy
WO2015187848A1 (en) * 2014-06-04 2015-12-10 Sampath Deepa Hdac inhibitor and btk inhibitor combinations
US20160022684A1 (en) * 2014-07-25 2016-01-28 Pharmacyclics Llc Bet inhibitor and bruton's tyrosine kinase inhibitor combinations
KR20170044172A (ko) * 2014-08-28 2017-04-24 온코에틱스 게엠베하 티에노트리아졸로디아제핀 화합물을 함유하는 약학적 조성물을 사용하여 급성 골수성 백혈병 또는 급성 림프구성 백혈병을 치료하는 방법
US9604927B2 (en) * 2014-10-09 2017-03-28 Oncternal Therapeutics, Inc. Indolinone compounds and uses thereof
KR102375929B1 (ko) 2016-03-31 2022-03-16 온크터널 테라퓨틱스, 인코포레이티드. 인돌린 유사체 및 이의 용도
CN114569606B (zh) * 2016-07-29 2024-04-19 英克特诺治疗公司 吲哚啉酮化合物的用途
US20190255127A1 (en) 2018-02-21 2019-08-22 Batu Biologics, Inc. Augmentation of Oncolytic Viral Efficacy through Immunological Targeting Tumor Endothelial Cells

Similar Documents

Publication Publication Date Title
JP2019522037A5 (OSRAM)
WO2019006005A3 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF MELANOMA
MX2024010140A (es) Nuevos metodos.
WO2017042607A3 (en) Compositions comprising meloxicam-cyclodextrin inclusion complexes and methods of treating acute pain
WO2017091749A8 (en) Shape changing drug delivery devices and methods
JP2015057451A5 (OSRAM)
WO2015165413A8 (zh) 一种新型的稳定型抗体药物耦联物及其制备方法和用途
WO2015121348A3 (en) Pharmaceutical composition comprising erythrocytes encapsulating a plp-dependent enzyme and its cofactor
PH12018501903B1 (en) Methods of treating depression using orexin-2 receptor antagonists
EP3682875A3 (en) Methods of treating pediatric metabolic syndrome
MY189466A (en) Methods of modulating drug plasma levels using erythrohydroxybupropion
MX2016006318A (es) 7-bencil-4-(2-metilbencil)-2,4,6,7,8,9-hexahidroimidazo[1,2-a]pir ido[3,4-e]pirimidin-5(1h)-ona, sales de la misma y metodos de uso.
TN2016000083A1 (en) Methods and tools relating to the administration of contrast medium
SG10201906172XA (en) Regulation of glucose metabolism using anti-cgrp antibodies
PH12017501304A1 (en) Levodopa and carbidopa intestinal gel and method of use
HK1255481A1 (zh) 用於治疗hcv的方法
MX2016012722A (es) Metodos para tratar el virus de la hepatitis c.
MX2011009212A (es) Lipoatrofia cosmetica medicinal.
NZ712584A (en) Antitumor agent including irinotecan hydrochloride hydrate
CO2020000529A2 (es) Metodos para tratar hiperinsulinismo congenito
JP2019518052A5 (OSRAM)
ME02839B (me) Derivati indolouree supstituirani glukopiranozilom i njihova upotreba kao inhibitora sglt
UA117105U (uk) Спосіб застосування препарату xyla для анестезії плідників осетрових в процесі штучного відтворення
Chiu et al. Airway inflammation in asthma
HK1214511A1 (zh) 盐酸兰地洛尔在快速性心律失常的长期治疗中的用途